Cargando…

A Randomized Controlled Trial of Norepinephrine Plus Dobutamine Versus Epinephrine As First-Line Vasoactive Agents in Children With Fluid Refractory Cold Septic Shock

Our objective was to compare norepinephrine plus dobutamine versus epinephrine as the first-line agent in children with fluid refractory cold septic shock. DESIGN: Open-label randomized controlled study. SETTING: A single-center PICU from North India. PATIENTS: Children 2 months to less than 18 year...

Descripción completa

Detalles Bibliográficos
Autores principales: Banothu, Kiran Kumar, Sankar, Jhuma, Kumar, U. Vijaya, Gupta, Priyanka, Pathak, Mona, Jat, Kana Ram, Kabra, Sushil Kumar, Lodha, Rakesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9799172/
https://www.ncbi.nlm.nih.gov/pubmed/36600781
http://dx.doi.org/10.1097/CCE.0000000000000815
_version_ 1784861054738628608
author Banothu, Kiran Kumar
Sankar, Jhuma
Kumar, U. Vijaya
Gupta, Priyanka
Pathak, Mona
Jat, Kana Ram
Kabra, Sushil Kumar
Lodha, Rakesh
author_facet Banothu, Kiran Kumar
Sankar, Jhuma
Kumar, U. Vijaya
Gupta, Priyanka
Pathak, Mona
Jat, Kana Ram
Kabra, Sushil Kumar
Lodha, Rakesh
author_sort Banothu, Kiran Kumar
collection PubMed
description Our objective was to compare norepinephrine plus dobutamine versus epinephrine as the first-line agent in children with fluid refractory cold septic shock. DESIGN: Open-label randomized controlled study. SETTING: A single-center PICU from North India. PATIENTS: Children 2 months to less than 18 years old with fluid refractory cold septic shock. INTERVENTIONS: In the intervention group, norepinephrine and dobutamine were started and in the control group, epinephrine was started as the first-line vasoactive agent. The primary outcome was the proportion attaining shock resolution (attaining all the therapeutic endpoints) at 1 hour of therapy. MEASUREMENTS AND MAIN RESULTS: We enrolled 67 children: 34 in the norepinephrine plus dobutamine group (intervention) and 33 in the epinephrine group (control). There was no difference in shock resolution at 1 hour (17.6% vs 9%; risk ratio [RR], 2.0; 95% CI, 0.54–7.35; p = 0.25), 6 hours (76.4% vs 54.5%; RR, 1.69; 95% CI, 0.92–3.13; p = 0.06), and 24 hours between the intervention and control groups, respectively. Children in the norepinephrine plus dobutamine group attained shock resolution earlier (measured from starting of vasoactive agents to attaining all the therapeutic endpoints) (hazard ratio, 1.84 [1.1–3.08]). The difference in 28-day mortality was not significant (23.5% vs 39.3% in the intervention and control groups, respectively [RR, 0.59; 95% CI, 0.28–1.25]). CONCLUSIONS: In children with fluid refractory cold septic shock, with use of norepinephrine plus dobutamine as first-line agents, the difference in the proportion of children attaining shock resolution at 1 hour between the groups was inconclusive. However, the time to shock resolution was earlier in the norepinephrine plus dobutamine group. Also, fewer children in the intervention group were refractory to treatment. Further studies powered to detect (or exclude) an important difference would be required to test this intervention.
format Online
Article
Text
id pubmed-9799172
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-97991722023-01-03 A Randomized Controlled Trial of Norepinephrine Plus Dobutamine Versus Epinephrine As First-Line Vasoactive Agents in Children With Fluid Refractory Cold Septic Shock Banothu, Kiran Kumar Sankar, Jhuma Kumar, U. Vijaya Gupta, Priyanka Pathak, Mona Jat, Kana Ram Kabra, Sushil Kumar Lodha, Rakesh Crit Care Explor Original Clinical Report Our objective was to compare norepinephrine plus dobutamine versus epinephrine as the first-line agent in children with fluid refractory cold septic shock. DESIGN: Open-label randomized controlled study. SETTING: A single-center PICU from North India. PATIENTS: Children 2 months to less than 18 years old with fluid refractory cold septic shock. INTERVENTIONS: In the intervention group, norepinephrine and dobutamine were started and in the control group, epinephrine was started as the first-line vasoactive agent. The primary outcome was the proportion attaining shock resolution (attaining all the therapeutic endpoints) at 1 hour of therapy. MEASUREMENTS AND MAIN RESULTS: We enrolled 67 children: 34 in the norepinephrine plus dobutamine group (intervention) and 33 in the epinephrine group (control). There was no difference in shock resolution at 1 hour (17.6% vs 9%; risk ratio [RR], 2.0; 95% CI, 0.54–7.35; p = 0.25), 6 hours (76.4% vs 54.5%; RR, 1.69; 95% CI, 0.92–3.13; p = 0.06), and 24 hours between the intervention and control groups, respectively. Children in the norepinephrine plus dobutamine group attained shock resolution earlier (measured from starting of vasoactive agents to attaining all the therapeutic endpoints) (hazard ratio, 1.84 [1.1–3.08]). The difference in 28-day mortality was not significant (23.5% vs 39.3% in the intervention and control groups, respectively [RR, 0.59; 95% CI, 0.28–1.25]). CONCLUSIONS: In children with fluid refractory cold septic shock, with use of norepinephrine plus dobutamine as first-line agents, the difference in the proportion of children attaining shock resolution at 1 hour between the groups was inconclusive. However, the time to shock resolution was earlier in the norepinephrine plus dobutamine group. Also, fewer children in the intervention group were refractory to treatment. Further studies powered to detect (or exclude) an important difference would be required to test this intervention. Lippincott Williams & Wilkins 2022-12-28 /pmc/articles/PMC9799172/ /pubmed/36600781 http://dx.doi.org/10.1097/CCE.0000000000000815 Text en Copyright © 2022 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Original Clinical Report
Banothu, Kiran Kumar
Sankar, Jhuma
Kumar, U. Vijaya
Gupta, Priyanka
Pathak, Mona
Jat, Kana Ram
Kabra, Sushil Kumar
Lodha, Rakesh
A Randomized Controlled Trial of Norepinephrine Plus Dobutamine Versus Epinephrine As First-Line Vasoactive Agents in Children With Fluid Refractory Cold Septic Shock
title A Randomized Controlled Trial of Norepinephrine Plus Dobutamine Versus Epinephrine As First-Line Vasoactive Agents in Children With Fluid Refractory Cold Septic Shock
title_full A Randomized Controlled Trial of Norepinephrine Plus Dobutamine Versus Epinephrine As First-Line Vasoactive Agents in Children With Fluid Refractory Cold Septic Shock
title_fullStr A Randomized Controlled Trial of Norepinephrine Plus Dobutamine Versus Epinephrine As First-Line Vasoactive Agents in Children With Fluid Refractory Cold Septic Shock
title_full_unstemmed A Randomized Controlled Trial of Norepinephrine Plus Dobutamine Versus Epinephrine As First-Line Vasoactive Agents in Children With Fluid Refractory Cold Septic Shock
title_short A Randomized Controlled Trial of Norepinephrine Plus Dobutamine Versus Epinephrine As First-Line Vasoactive Agents in Children With Fluid Refractory Cold Septic Shock
title_sort randomized controlled trial of norepinephrine plus dobutamine versus epinephrine as first-line vasoactive agents in children with fluid refractory cold septic shock
topic Original Clinical Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9799172/
https://www.ncbi.nlm.nih.gov/pubmed/36600781
http://dx.doi.org/10.1097/CCE.0000000000000815
work_keys_str_mv AT banothukirankumar arandomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock
AT sankarjhuma arandomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock
AT kumaruvijaya arandomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock
AT guptapriyanka arandomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock
AT pathakmona arandomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock
AT jatkanaram arandomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock
AT kabrasushilkumar arandomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock
AT lodharakesh arandomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock
AT banothukirankumar randomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock
AT sankarjhuma randomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock
AT kumaruvijaya randomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock
AT guptapriyanka randomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock
AT pathakmona randomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock
AT jatkanaram randomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock
AT kabrasushilkumar randomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock
AT lodharakesh randomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock